pre-IPO PHARMA

COMPANY OVERVIEW

Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. We are developing SJX-653, a novel and selective neurokinin 3 (NK3) antagonist, as an oral, once-daily, non-hormonal therapy for moderate to severe vasomotor symptoms due to menopause (commonly called “hot flashes”). Vasomotor symptoms (VMS) are sudden sensations of intense heat, sweating, and skin reddening which can occur frequently, disrupting both sleep and daily activities, and are associated with increased rates of insomnia, depression, and anxiety. Highly prevalent among menopausal women, VMS typically persist for many years during and after menopause. Current treatment options are limited to hormone therapy, which is often avoided due to safety concerns, or non-hormonal agents known to have limited efficacy. NK3 antagonism is a clinically and genetically validated new approach that targets the underlying cause of VMS by reducing excessive NK3 signaling in the area of the brain that regulates heat dissipation.


LOCATION

  • Waltham, MA, USA

  • THERAPEUTIC AREAS

  • Endocrine Disease
  • Women's Health

  • WEBSITE

    https://www.sojournixpharma.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    boxer-capital frazier-healthcare janus-henderson-investors ra-capital venrock


    PRESS RELEASES


    Dec 8, 2020

    Sojournix Advances Phase 2 Clinical Trial of SJX‑653 for Menopausal Hot Flashes


    Nov 17, 2020

    Sojournix to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference


    Sep 28, 2020

    Sojournix Presents Data at NAMS Showing SJX-653 Exhibits Potent NK3 Antagonist Profile Across Nonclinical and Initial Clinical Studies in Men and Postmenopausal Women


    Sep 21, 2020

    Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology and Metabolism


    Feb 24, 2020

    Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes


    For More Press Releases


    Google Analytics Alternative